Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

2004 • 11,185 citations

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

2004 • 9,201 citations

Untangling the ErbB signalling network

2001 • 6,623 citations

Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor

1999 • 6,443 citations

The phosphatidylinositol 3-Kinase–AKT pathway in human cancer

2002 • 5,914 citations

PTEN , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer

1997 • 4,753 citations

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

2005 • 3,450 citations

The Tumor Suppressor, PTEN/MMAC1, Dephosphorylates the Lipid Second Messenger, Phosphatidylinositol 3,4,5-Trisphosphate

1998 • 3,053 citations

Epidermal growth factor-related peptides and their receptors in human malignancies

1995 • 2,689 citations

Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers

2005 • 2,285 citations

KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer

2006 • 2,187 citations

Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity.

1986 • 1,866 citations

Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome

2005 • 1,834 citations

Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias

2006 • 1,734 citations

Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1

2004 • 1,733 citations

Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2

2004 • 1,723 citations

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

2002 • 1,717 citations

Epithelial–mesenchymal transitions in development and pathologies

2003 • 1,700 citations

TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer

2005 • 1,517 citations

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

2005 • 1,510 citations

Epithelial-Mesenchymal Transitions

2004 • 1,470 citations

Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib

2005 • 1,467 citations

AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1

2000 • 1,431 citations

Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors

2005 • 1,418 citations

Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors.

2000 • 1,310 citations

Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor

2002 • 1,308 citations

Direct control of the Forkhead transcription factor AFX by protein kinase B

1999 • 1,080 citations

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR

2001 • 981 citations

Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non–Small-Cell Lung Cancer With Postoperative Recurrence

2005 • 965 citations

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

2005 • 948 citations

Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells

2006 • 897 citations

Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib

2005 • 782 citations

Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer

2006 • 710 citations

ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer.

1996 • 675 citations

Structure and function of phosphoinositide 3-kinases

1998 • 666 citations

Cyclooxygenase-2: A Therapeutic Target

2002 • 656 citations

Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.

2001 • 642 citations

Epithelial to Mesenchymal Transition Is a Determinant of Sensitivity of Non–Small-Cell Lung Carcinoma Cell Lines and Xenografts to Epidermal Growth Factor Receptor Inhibition

2005 • 634 citations

Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors.

1995 • 633 citations

Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas

2005 • 619 citations

Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.

2002 • 607 citations

Forkhead Transcription Factors Are Critical Effectors of Cell Death and Cell Cycle Arrest Downstream of PTEN

2000 • 569 citations

Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor.

1993 • 554 citations

Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.

2001 • 545 citations

Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Non–Small-Cell Lung Cancer

2005 • 538 citations

Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology.

1993 • 534 citations

Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling.

2002 • 508 citations

Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma.

2000 • 505 citations

Multiple Signaling Pathways of the Insulin-Like Growth Factor 1 Receptor in Protection from Apoptosis

1999 • 499 citations

Restoring E-Cadherin Expression Increases Sensitivity to Epidermal Growth Factor Receptor Inhibitors in Lung Cancer Cell Lines

2006 • 491 citations

Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients

2005 • 490 citations

Cell communication networks: epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission

2001 • 463 citations

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

2003 • 457 citations

Epidermal Growth Factor Receptor Mutations in Non–Small-Cell Lung Cancer: Implications for Treatment and Tumor Biology

2005 • 403 citations

The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells.

1998 • 393 citations

Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR) ‐dependent signaling

2002 • 378 citations

Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.

2000 • 376 citations

Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy

2004 • 341 citations

Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib

2006 • 336 citations

Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment.

2003 • 333 citations

Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.

2003 • 326 citations

p42/p44 MAP Kinase Module Plays a Key Role in the Transcriptional Regulation of the Vascular Endothelial Growth Factor Gene in Fibroblasts

1998 • 321 citations

Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.

2003 • 318 citations

Treatment of Metastatic Renal Cell Carcinoma With a Combination of Bevacizumab and Erlotinib

2005 • 310 citations

Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC)

2004 • 301 citations

Single-Chain Antibody-Mediated Intracellular Retention of ErbB-2 Impairs Neu Differentiation Factor and Epidermal Growth Factor Signaling

1995 • 300 citations

Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells

2004 • 298 citations

EGF receptor in neoplasia and metastasis

1993 • 297 citations

Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members.

1999 • 293 citations

Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.

2003 • 284 citations

Vascular Endothelial Growth Factor Receptor-1 Activation Mediates Epithelial to Mesenchymal Transition in Human Pancreatic Carcinoma Cells

2006 • 260 citations

The Epidermal Growth Factor Receptor Modulates the Interaction of E-cadherin with the Actin Cytoskeleton

1998 • 259 citations

Identification of Domains of the Insulin-Like Growth Factor I Receptor That Are Required for Protection from Apoptosis

1997 • 258 citations

Transforming growth factor-alpha -induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP-2-dependent DNA binding and transactivation

1997 • 256 citations

Crystal structure of the first three domains of the type-1 insulin-like growth factor receptor

1998 • 253 citations

The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.

2002 • 248 citations

PTEN regulates the ubiquitin-dependent degradation of the CDK inhibitor p27KIP1 through the ubiquitin E3 ligase SCFSKP2

2001 • 223 citations

Epidermal growth factor receptor signaling

2001 • 211 citations

Activation of BAD by Therapeutic Inhibition of Epidermal Growth Factor Receptor and Transactivation by Insulin-like Growth Factor Receptor

2002 • 208 citations

Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association.

2001 • 192 citations

Neu Differentiation Factor Activation of ErbB-3 and ErbB-4 Is Cell Specific and Displays a Differential Requirement for ErbB-2

1995 • 187 citations

When kinases meet mathematics: the systems biology of MAPK signalling

2005 • 180 citations

Blockade of receptors for growth factors: an anticancer therapy--the fourth annual Joseph H Burchenal American Association of Cancer Research Clinical Research Award Lecture.

2000 • 179 citations

Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin

2004 • 167 citations

Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 (‘Iressa’)

2002 • 157 citations

Resistance to Tyrosine Kinase Inhibition by Mutant Epidermal Growth Factor Receptor Variant III Contributes to the Neoplastic Phenotype of Glioblastoma Multiforme

2004 • 156 citations

Synergistic Interaction of the Neu Proto-Oncogene Product and Transforming Growth Factor α in the Mammary Epithelium of Transgenic Mice

1996 • 146 citations

Tumour vasculature as a target for anticancer therapy

2000 • 139 citations

Establishment of a human non‐small cell lung cancer cell line resistant to gefitinib

2005 • 132 citations

Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment.

2001 • 130 citations

Adenovirus-mediated gene transfer of MMAC1/PTEN to glioblastoma cells inhibits S phase entry by the recruitment of p27Kip1 into cyclin E/CDK2 complexes.

1999 • 121 citations

Deregulated Cyclin D1 Expression Is Associated with Decreased Efficacy of the Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib in Head and Neck Squamous Cell Carcinoma Cell Lines

2004 • 112 citations

ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two-part, double-blind, randomized phase II trial

2006 • 110 citations

The Mitogenic Action of Insulin-like Growth Factor I in Normal Human Mammary Epithelial Cells Requires the Epidermal Growth Factor Receptor Tyrosine Kinase

2004 • 110 citations

Disruption of Parallel and Converging Signaling Pathways Contributes to the Synergistic Antitumor Effects of Simultaneous mTOR and EGFR Inhibition in GBM Cells

2005 • 95 citations

Prognostic influence of the co-expression of epidermal growth factor receptor and c-erbB-2 protein in human lung adenocarcinoma

1994 • 87 citations

High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo.

2001 • 75 citations

Distinct mechanisms mediate the initial and sustained phases of cell migration in epidermal growth factor receptor-overexpressing cells.

2003 • 73 citations

A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: Follow-up results

2006 • 73 citations

Kinase-deficient neu proteins suppress epidermal growth factor receptor function and abolish cell transformation.

1994 • 68 citations

Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer

2005 • 67 citations

Insulin-Like Growth Factor-I Receptors in Human Glial Tumors

1990 • 59 citations

The Price of Independence

1997 • 52 citations

An analysis of the prognostic and predictive importance of K-ras mutation status in the National Cancer Institute of Canada Clinical Trials Group BR.21 study of erlotinib versus placebo in the treatment of non-small cell lung cancer

2006 • 50 citations

Enhanced antiangiogenic therapy of squamous cell carcinoma by combined endostatin and epidermal growth factor receptor-antisense therapy.

2002 • 48 citations

The Roles of JNK1 and Stat3 in the Response of Head and Neck Cancer Cell Lines to Combined Treatment with All trans‐retinoic Acid and 5‐Fluorouracil

2002 • 40 citations

Schedule-dependent effects of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib in combination with the mammalian target of rapamycin (mTOR) inhibitor everolimus (RAD001)

2004 • 17 citations

Molecular analysis of NSCLC patients with acquired resistance to gefitinib or erlotinib

2006 • 12 citations

Schedule-dependent effects of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib in combination with the mammalian target of rapamycin (mTOR) inhibitor everolimus (RAD001)

2004 • 7 citations